A Phase II, Multi-site, Open-label, Parallel Group Trial of BNT327 in Combination With Chemotherapy for Participants With Untreated Extensive-stage Small-cell Lung Cancer and Participants With Previously Treated Small-cell Lung Cancer

This is a Phase II, multi-site, open-label, parallel group study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) progressed on first- or second-line treatment (Cohort 2 and Cohort 3).

开始日期2024-06-01

申办/合作机构

BioNTech SE

IRCT20201203049585N3 / Suspended临床2/3期

the effect of high power laser therapy on neuropathy induced by chemotherapy with taxane drugs in breast cancer patients

开始日期2023-08-23

申办/合作机构

Isfahan University of Medical Sciences

JPRN-UMIN000042218 / Completed

The efficacy and safety of taxane therapy after discontinuation of nivolumab therapy in Japanese patients with advanced or recurrent esophageal cancer:a retrospective observational study (AFTER NIVO ESO Study) - AFTER NIVO ESO study

开始日期2021-01-01

申办/合作机构-

100 项与紫杉烷相关的临床结果

登录后查看更多信息

100 项与紫杉烷相关的转化医学

登录后查看更多信息

100 项与紫杉烷相关的专利（医药）

登录后查看更多信息

6,353

项与紫杉烷相关的文献（医药）

2024-04-01·International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Phase I study of ombrabulin in combination with paclitaxel and carboplatin in Japanese patients with advanced solid tumors

Article

作者: Ecstein-Fraisse, Evelyne ; Matsumoto, Koji ; Sunaga, Yoshinori ; Fujiwara, Keiichi

Objectives:

To evaluate the maximum tolerated dose/maximum administered dose, safety, pharmacokinetic, and efficacy profiles of ombrabulin combined with paclitaxel and carboplatin in Japanese patients with solid tumors.

Methods:

Ombrabulin (25, 30, or 35 mg/m2) combined with paclitaxel (175 or 200 mg/m2) and carboplatin (AUC5 or AUC6) was administered by intravenous infusion once every 3 weeks to patients with advanced solid tumors, including cervical, ovarian, and uterine cancers. The maximum tolerated dose/maximum administered dose was defined based on the dose-limiting toxicity at cycle 1. Efficacy was assessed based on Response Evaluation Criteria In Solid Tumors (RECIST).

Results:

In total, 18 patients were recruited for this dose escalation study. One out of six patients treated with the highest doses of combination of ombrabulin (35 mg/m2), paclitaxel (200 mg/m2), and carboplatin (AUC6) presented a dose-limiting toxicity consisting of grade 3Escherichiaurinary tract infection. This dose was defined as the maximum tolerated dose of ombrabulin. The most frequent treatment-emergent adverse events were alopecia (83.3%), neutropenia and fatigue (72.2% each), decreased appetite, nausea, diarrhea, arthralgia, and myalgia (66.7% each). The grade 3–4 treatment-emergent adverse events included neutropenia (61.1%),Escherichiaurinary tract infection, drug hypersensitivity, syncope, pulmonary embolism, and hydronephrosis (one patient each). In efficacy evaluation, seven patients achieved partial response or better (38.9%), including one complete response, and seven of 18 patients had stable disease (38.9%). Pharmacokinetic profiles in this Japanese study were comparable with those observed in the previous study without Japanese patients.

Conclusions:

Although the maximum tolerated dose/maximum administered dose of ombrabulin (35 mg/m2) with taxane-platinum combination may be tolerable in Japanese patients in the first cycle, the dosages in the repeated treatment should be carefully selected for further study.

Trial registration number:

NCT01293630.

2024-04-01·Indian journal of clinical biochemistry : IJCB

Circulating miRNA-21 Levels in Breast Cancer Patients Before and After Chemotherapy and Its Association with Clinical Improvement

Article

作者: Elhence, Poonam Abhay ; Vishnoi, Jeewan Ram ; Garg, Pawan Kumar ; Varthya, Shobhan Babu ; Ambwani, Sneha ; Charan, Jaykaran ; Purohit, Purvi ; Sukhija, Sanchi ; Pareek, Puneet ; Sharma, Praveen

Breast cancer is the most frequent type of cancer in women, many patients experience recurrences and metastasis. miR-21 (microRNA-21) as biomarker is under investigation for breast cancer. At present, there is very limited information available regarding effect of chemotherapy on miR-21 expression in breast cancer and its correlation with the clinical improvement. Hence, this study was planned to evaluate the effect of chemotherapy on miR-21 in metastatic breast cancer and its relationship with the clinical outcome. Females, aged-18-90 years diagnosed with Invasive Ductal Carcinoma of breast and candidate of neoadjuvant chemotherapy including Adriamycin (60 mg/m²), Cyclophosphamide (600 mg/m²) with or without Taxane (75-175 mg/m²) were included in the study. Before and after 42 days of staring of chemotherapy sample was collected for circulatory miR-21 and RECIST 1.1 criteria was applied to assess the clinical status. Blood samples for routine clinical biomarkers including liver function test and renal function tests was also collected. miR-21 expression before and after chemotherapy was assessed using standard method based on real time PCR. Expression of miR-21, RECIST criteria and other liver and kidney related biomarkers were compared before and after chemotherapy. After neoadjuvant chemotherapy expression of miR-21 was significantly increased by 5.65-fold. There was significant improvement in clinical scores based on RECIST criteria (0.046). No significant correlation was observed between miR-21 expression and difference in RECIST score (r = - 0.122, p = 0.570). Neoadjuvant chemotherapy causes clinical improvement in breast cancer patients however it is not correlated with the miR-21 expression which significantly increased after chemotherapy.

2024-04-01·Cancer pathogenesis and therapy

Efficacy and safety of utidelone for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer who have failed standard second-line treatment: A phase 2 clinical trial (BG01-1801)

Article

作者: Chen, Gongyan ; Zhao, Jing ; Shi, Yuankai ; Zhao, Yanqiu ; Lin, Lin

Background:

Chemotherapy remains the standard-of-care for many patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC), but acquired resistance presents challenges. The aim of this open-label, multicenter phase 2 clinical trial was to determine the efficacy and safety of utidelone, a novel genetically engineered epothilone analog and microtubule-stabilizing agent, as a third- or later-line treatment for locally advanced or metastatic NSCLC.

Methods:

Patients who had failed standard second-line treatment (including platinum-containing chemotherapy or targeted therapy) received utidelone (40 mg/m² via intravenous injection daily, day 1-5) every 21 days. The primary endpoint was the objective response rate (ORR). Secondary endpoints were the duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety.

Results:

From March 12, 2019 to January 18, 2021, 26 pretreated patients with locally advanced or metastatic NSCLC (100% of patients had received prior platinum and 65.4% patients had received prior taxane treatment) were enrolled (80.8% of patients had adenocarcinoma). At baseline, nine (34.6%) patients had received second-line treatment, 10 (38.5%) patients had received third-line treatment, and seven (26.9%) patients had received fourth- or later-line treatment. By the data cut-off date of August 10, 2021, the median follow-up was 7.49 months (range, 1.4-26.7 months). The ORR was 15.4% (95% confidence interval [CI], 4.4%-34.9%) in the intention-to-treat (ITT) cohort (N = 26) and 19.0% (95% CI, 5.4%-41.9%) in the per-protocol (PP) cohort (N = 21). The disease control rate was 69.2% (95% CI, 48.2%-85.7%) and 81.0% (95% CI, 58.1%-94.6%) in the ITT and PP cohorts, respectively. The median DoR was 4.1 months (95% CI, 3.1-5.1 months) in the ITT cohort. The median PFS was 4.37 months (95% CI, 2.50-5.29 months) in the ITT cohort and 4.37 months (95% CI, 2.50-9.76 months) in the PP cohort. The median OS was not reached, and the 12-month OS rate was 69% (95% CI, 45.1%-84.1%). Grade 3/4 treatment-emergent adverse events occurred in 38.5% of patients, and the most common was peripheral neuropathy (23.1%, all Grade 3), which was manageable with dose modifications.

Conclusions:

In this clinical trial, utidelone showed promising efficacy and had a manageable safety profile. Further clinical studies are warranted to confirm its role in NSCLC treatment.

Trial registration:

No.NCT03693547; https://classic.clinicaltrials.gov.

222

项与紫杉烷相关的新闻（医药）

2024-06-11

·PRNewswire

Global Anti-Radiation Drugs Market to Register Incremental Growth at a CAGR of ~9% by 2030 | DelveInsight

The rise in demand for anti-radiation drugs is mainly driven by several factors. These include the growing occurrence of side effects linked to cancer screening methods, heightened risks of exposure to radiological or nuclear emergencies, and the increasing focus of nuclear-capable nations on safeguarding against radiation. These trends are expected to fuel the expansion of the anti-radiation drugs market from 2024 to 2030. LAS VEGAS, June 11, 2024 /PRNewswire/ -- DelveInsight's Anti-Radiation Drugs Market Insights report provides the current and forecast market analysis, individual leading anti-radiation drugs companies' market shares, challenges, anti-radiation drugs market drivers, barriers, trends, and key market anti-radiation drugs companies in the market. Key Takeaways from the Anti-Radiation Drugs Market Report As per DelveInsight estimates, North America is anticipated to dominate the global anti-radiation drugs market during the forecast period. In the compound type segment of the anti-radiation drugs market, the Potassium iodide sub-category had a significant revenue share in the year 2023. This can be ascribed to the various characteristics and advantages associated with potassium iodide. Notable anti-radiation drugs companies such as Novartis AG, Anbex Inc., Amgen Inc., Myelo Therapeutics, Arco Pharmaceuticals LLC, BTG International Inc., Cellphire Inc., Darnitsa, Enzychem Lifesciences Corporation, Humanetics Corporation, Mission Pharmacal Company, Chrysalis BioTherapeutics Inc., Pluri Inc., Partner Therapeutics, HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG., RxBio Inc., Coherus Biosciences, Onconova Therapeutics, Jubilant Life Sciences, Soligenix Inc., and several others, are currently operating in the anti-radiation drugs market. In September 2023, the U.S. Department of Defense awarded Edina-based Humanetics a USD 20 million contract to develop a pill that prevents radiation damage in military members and first responders affected by events such as nuclear accidents, warfare, and dirty bombs. In May 2023, the first-in-human clinical trial of an experimental oral drug for removing radioactive contaminants from inside the body, testing the safety, tolerability, and processing in the body of escalating doses of the investigational drug product HOPO 14-1 was initiated in healthy adults. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, was funding the Phase 1 trial, which was sponsored and conducted by SRI International of Menlo Park, California. In March 2022, Novartis announced that the US Food and Drug Administration (FDA) approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body. These patients have already been treated with other anticancer treatments (androgen receptor pathway inhibition and taxane-based chemotherapy). To read more about the latest highlights related to the anti-radiation drugs market, get a snapshot of the key highlights entailed in the Global Anti-Radiation Drugs Market Report Anti-Radiation Drugs Overview Anti-radiation drugs are pharmaceutical compounds designed to mitigate the damaging effects of radiation exposure on the human body. These drugs work by either scavenging free radicals generated by radiation or by enhancing the repair mechanisms of cells damaged by radiation. One class of anti-radiation drugs includes radioprotectors, which are administered before radiation exposure to prevent or reduce its harmful effects. Another class, known as radiomitigators, is given after exposure to alleviate the severity of radiation-induced damage. These drugs hold significant promise in scenarios such as nuclear accidents, medical radiation therapy, and space travel, where the risk of radiation exposure is a concern. Research into anti-radiation drugs is ongoing, with scientists continually striving to improve their efficacy and minimize side effects. Some compounds under investigation show potential not only in protecting against acute radiation sickness but also in mitigating long-term effects such as cancer development. As our understanding of radiation biology advances, coupled with advancements in drug development technologies, the prospects for more effective and accessible anti-radiation drugs continue to brighten, offering hope for safer environments in radiation-prone situations. Anti-Radiation Drugs Market Insights In 2023, North America dominated the anti-radiation drugs market, primarily due to several factors contributing to growth. These include a substantial patient population afflicted with various illnesses like cancer, increasing numbers of diagnostic procedures, and governmental initiatives aimed at public health in the region. This trend is expected to continue from 2024 to 2030. The prevalence of cancer in the United States, for example, drives a significant demand for anti-radiation drugs. Statistics from the American Cancer Society projected around 2 million new cancer cases in the United States in 2024, leading to heightened demand for these drugs to support cancer diagnostic procedures. Additionally, the US benefits from a strong focus on clinical research and the presence of leading pharmaceutical companies, further bolstering the market for anti-radiation drugs. Moreover, in 2022, the US Department of Health and Human Services (HHS) allocated USD 290 million for the purchase of Nplate, a drug produced by Amgen USA Inc., intended to treat radiation sickness in the event of a nuclear emergency. This investment reflects ongoing efforts to enhance preparedness for radiological and nuclear emergencies and underscores the commitment to saving lives in such scenarios. To know more about why North America is leading the market growth in the anti-radiation drugs market, get a snapshot of the Anti-Radiation Drugs Market Outlook Anti-Radiation Drugs Market Dynamics The market dynamics of anti-radiation drugs are driven by a complex interplay of factors ranging from technological advancements to geopolitical events and regulatory frameworks. One of the primary drivers is the increasing threat of radiation exposure from various sources such as nuclear accidents, medical procedures, and potential radiological terrorism. This heightened awareness has propelled research and development efforts to create effective anti-radiation drugs that can mitigate the harmful effects of radiation exposure. Moreover, the growing prevalence of cancer and the widespread use of radiation therapy as a treatment modality has further fueled the demand for anti-radiation drugs. As more individuals undergo radiation-based treatments, there is a parallel need for medications that can protect healthy tissues and organs from the damaging effects of ionizing radiation. The competitive landscape of the anti-radiation drugs market is characterized by both established pharmaceutical companies and innovative startups vying for market share. Established players often leverage their resources and expertise to develop and commercialize new anti-radiation drugs, while startups focus on disruptive technologies and novel approaches to address unmet needs in radiation protection. Government initiatives and regulatory frameworks also play a crucial role in shaping the market dynamics of anti-radiation drugs. Regulatory agencies set standards for safety, efficacy, and quality assurance, which impact the development, approval, and commercialization of these medications. Additionally, government investments in research and development, as well as funding for procurement and stockpiling of anti-radiation drugs for emergency preparedness, influence market dynamics. Overall, the anti-radiation drugs market is characterized by a dynamic landscape driven by technological innovation, healthcare trends, regulatory factors, and geopolitical considerations. As the threat of radiation exposure continues to evolve, so too will the demand for effective anti-radiation drugs, driving further growth and innovation in this important sector of the pharmaceutical industry. Get a sneak peek at the anti-radiation drugs market dynamics @ Anti-Radiation Drugs Market Dynamics Analysis Anti-Radiation Drugs Market Assessment Anti-Radiation Drugs Market Segmentation Anti-Radiation Drugs Market Segmentation By Compound: Potassium Iodide, Prussian Blue, Diethylenetriamine Pentaacetic Acid, Colony Stimulating Factors, and Others Anti-Radiation Drugs Market Segmentation By Indication: Acute Radiation Syndrome, Cancer Treatment, and Others Anti-Radiation Drugs Market Segmentation By Radiation Type: Ionizing Radiations and Non-Ionizing Radiations Anti-Radiation Drugs Market Segmentation By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, and Others Anti-Radiation Drugs Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of World Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View Which MedTech key players in the anti-radiation drugs market are set to emerge as the trendsetter explore @ Anti-Radiation Drugs Companies Table of Contents Interested in knowing the anti-radiation drugs market by 2030? Click to get a snapshot of the Anti-Radiation Drugs Market Trends Related Reports Cancer Biomarkers Market Cancer Biomarkers Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer biomarkers companies, including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Inc., QIAGEN N.V., Illumina, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, bioMérieux SA, BD, Merck Millipore, Agilent Technologies, Myriad Genetics, Sysmex Corporation, Hologic, Inc., Quest Diagnostics, Centogene N.V., PerkinElmer, Inc., Siemens Healthineers, Exact Sciences, R&D Systems, Inc., BioVision, Inc., among others. Cancer Therapy Market Cancer Therapy Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key cancer therapy companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc, Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, Elekta AB, Varian Medical Systems, Inc., Accuray Incorporated, Pyrexar Medical, Eckert & Ziegler, IBA, Panacea Medical Technologies Pvt. Ltd., among others. Oncology Drugs Market Oncology Drugs Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key oncology drugs companies, including GlaxoSmithKline, Eli Lilly & Company, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Sanofi, Merck & Co., Inc, Novartis AG, Pfizer Inc, AstraZeneca, Bristol Myers Squibb., Gilead Sciences, Inc., Janssen Global Services, LLC, BAYER AG., Celldex Therapeutics Inc., Alaunos Therapeutics, Inc., Astellas Pharma Inc., Genentech, Inc., Sandoz International GmbH, BeiGene, among others. Liquid Biopsy in Cancer Diagnostics Market Liquid Biopsy in Cancer Diagnostics Market Insight, Competitive Landscape, and Market Forecast – 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key liquid biopsy in cancer diagnostics companies, including Myriad Genetics Inc., Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health, Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd., among others. About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Contact Us Shruti Thakur [email protected] +14699457679 Logo: SOURCE DelveInsight Business Research, LLP

放射疗法

2024-06-10

·drugs

American Society of Clinical Oncology, May 30-June 4

The annual meeting of the American Society of Clinical Oncology was held from May 30 to June 4 in Chicago and hosted more than 34,000 participants from around the world, including clinicians, academicians, allied health professionals, and others interested in oncology. The conference featured the latest advances in clinical cancer research, including oral abstract presentations and poster presentations in disease-based and specialty tracks. Presentations focused on novel targeted therapies as well as improvements in chemotherapy and radiation therapy approaches. In one study, Jefferson DeKloe, M.D., of Thomas Jefferson University in Philadelphia, and colleagues found that human papillomavirus (HPV) vaccination reduces the risk for cervical cancer and precancerous dysplasia in female patients and may reduce the incidence of other HPV-associated cancers, including head and neck cancers in men. The authors performed a retrospective cohort study using the data from the TriNetX U.S. Collaborative Network. Patients aged 9 to 39 years who received any vaccine between Jan. 1, 2010, and Dec. 31, 2023, were included in the analysis. Patients were divided into two cohorts: those vaccinated for HPV at least five years prior and those with no history of HPV vaccination. The development of malignancies across various organ systems, including head and neck, cervix, anus and anal canal, penis, vulva, and vagina, was assessed. The researchers observed lower rates of cervical cancer in female participants vaccinated for HPV compared with those not vaccinated. Furthermore, lower rates of head and neck cancer were observed in male patients vaccinated for HPV compared with those not vaccinated. "There are still many variables that influence the risk of developing an HPV-associated cancer and future research may inform us what is causing the reduced incidence of head and neck cancers in HPV-vaccinated males," DeKloe said. "This work shows that the HPV-vaccination efforts in the United States may already have some apparent benefit measured through the reduction of HPV-associated cancers. Given the rise in HPV-related cancers in the past few decades, HPV vaccination is an important means of cancer prevention that should be emphasized for male and female patients in clinical practice." One author disclosed a financial relationship with AstraZeneca. Abstract No. 10507 In a large-scale comparative effectiveness trial across 22 cancer centers, Joseph Greer, M.D., of Massachusetts General Hospital and Harvard Medical School in Boston, and colleagues demonstrated equivalence for the effect of delivering early palliative care via video versus in-person visits on quality of life in patients with advanced lung cancer. The authors focused on the use of video visits to deliver palliative care, as according to the authors, they require fewer clinical resources and may be a more efficient way for clinicians to provide care. The researchers also note that video visits save patients time and money compared with going to the hospital or clinic to meet with the clinician. The trial included 1,250 patients, with 633 in the video-visit palliative care group and 617 in the in-person palliative care group. In addition, 548 caregivers (i.e., a family member or friend who was involved in the patient's care) were enrolled in the study. All patients who participated in the study received early palliative care that began soon after their diagnosis and continued throughout the course of their disease. Patients in both study groups had contact with the palliative care clinician every four weeks, with the visits occurring predominantly in clinic for those randomly assigned to in-person palliative care and via video visits for those assigned to telehealth palliative care. The researchers found that medical care, such as palliative care, can be delivered through video visits and patients and their family caregivers receive the same quality-of-life benefits as with in-person palliative care. The two study groups also did not differ in their reported satisfaction with care or with respect to patient- and caregiver-reported mood symptoms. "The equivalence of these modalities in a population with serious illness underscores the urgent need for clinicians, health care systems, and policymakers to expand equitable access to evidence-based palliative care and develop guidelines for a new standard of care that includes the broad adoption of telehealth services," Greer said. Several authors disclosed ties to the biopharmaceutical industry. Abstract No. LBA3 In a prospective study, Kimia Sorouri, M.D., of the Dana-Farber Cancer Institute in Boston, and colleagues followed breast cancer survivors over 10 years to determine fertility outcomes in those attempting pregnancy, with the majority achieving pregnancy and most experiencing live births. The authors evaluated women with stage 0 to III breast cancer included in the Young Women's Breast Cancer Study who reported attempting pregnancy postdiagnosis (1,213 eligible female participants, including 197 reporting any attempt of pregnancy). The researchers found that 73 percent reported at least one pregnancy after diagnosis and 65 percent experienced at least one live birth after diagnosis. "This is the first prospective study with greater than 10 years of follow-up to report fertility outcomes in young breast cancer survivors accounting for attempting pregnancy," the authors write. "Our findings can be incorporated into the counseling of young breast cancer patients and survivors, and highlight the need for accessibility of fertility preservation services for this population." Several authors disclosed ties to the pharmaceutical, medical device, and medical technology industries. Abstract No. 1518 ASCO: Germline Variation Does Not Predict Taxane-Induced Peripheral Neuropathy FRIDAY, June 7, 2024 -- Germline variation does not predict the risk of taxane-induced peripheral neuropathy in Black women receiving paclitaxel (once weekly) or docetaxel (every three weeks) for early-stage breast cancer, according to a study published online June 3 in the Journal of Clinical Oncology to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago. Read Full Text ASCO: Ivonescimab Improves Progression-Free Survival in EGFR + Lung Cancer THURSDAY, June 6, 2024 -- For patients with non-small cell lung cancer with the epidermal growth factor receptor variant, ivonescimab plus chemotherapy improves progression-free survival, according to a study published online May 31 in the Journal of the American Medical Association to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago. Read Full Text ASCO: Osimertinib Improves Progression-Free Survival in EGFR -Mutated Lung Cancer WEDNESDAY, June 5, 2024 -- For patients with unresectable stage III EGFR -mutated non-small cell lung cancer, treatment with osimertinib results in significantly longer progression-free survival, according to a study published online June 2 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago. Read Full Text ASCO: Neoadjuvant Ipilimumab + Nivolumab Ups Survival in Resectable Melanoma WEDNESDAY, June 5, 2024 -- Neoadjuvant ipilimumab plus nivolumab followed by surgery results in longer event-free survival than surgery followed by adjuvant nivolumab among patients with resectable, macroscopic stage III melanoma, according to a study published online June 2 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago. Read Full Text ASCO: Asciminib Has Superior Efficacy to TKIs for Newly Diagnosed Leukemia WEDNESDAY, June 5, 2024 -- For patients with newly diagnosed chronic myeloid leukemia, asciminib shows superior efficacy and a favorable safety profile compared with investigator-selected tyrosine kinase inhibitors, according to a study published online May 31 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago. Read Full Text ASCO: Stepped-Care Model Noninferior to Early Palliative Care for Advanced Cancer TUESDAY, June 4, 2024 -- For patients with advanced lung cancer, a stepped-care model with palliative care visits occurring at key points in patients' cancer trajectory is noninferior to early palliative care, according to a study published online June 2 in the Journal of the American Medical Association to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago. Read Full Text ASCO: Conjugated Equine Estrogen May Increase Risk for Ovarian Cancer TUESDAY, May 28, 2024 -- Conjugated equine estrogen taken alone for menopause may increase the risk for developing and dying from ovarian cancer, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago. Read Full Text ASCO: Survivors of Early Breast Cancer Can Successfully Attempt Pregnancy THURSDAY, May 23, 2024 -- Most survivors of stage 0 to III breast cancer who attempt pregnancy postdiagnosis are able to become pregnant and have a live birth, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago. Read Full Text ASCO: HPV Vaccination Positively Affecting More Than Just Cervical Cancer Risk THURSDAY, May 23, 2024 -- Human papillomavirus vaccination is associated with reduced odds of several types of HPV-related cancers, not just cervical cancer, according to a study presented at the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago. Read Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

ASCO会议临床结果

2024-06-07

·drugs

ASCO: Germline Variation Does Not Predict Taxane-Induced Peripheral Neuropathy

FRIDAY, June 7, 2024 -- Germline variation does not predict the risk of taxane-induced peripheral neuropathy (TIPN) in Black women receiving paclitaxel (once weekly) or docetaxel (every three weeks) for early-stage breast cancer, according to a study published online June 3 in the Journal of Clinical Oncology to coincide with the annual meeting of the American Society of Clinical Oncology, held from May 31 to June 4 in Chicago. Bryan P. Schneider, M.D., from the Indiana University Melvin and Bren Simon Comprehensive Cancer Center in Indianapolis, and colleagues validated germline predictors of TIPN and compared rates of TIPN and dose reductions in Black women receiving (neo)adjuvant paclitaxel once weekly and docetaxel once every three weeks for early-stage breast cancer. Germline neuropathy risk was determined by performing genotyping; genotype data were available for 240 patients. Of the patients, 91 of 117 receiving once-weekly paclitaxel and 87 of 118 receiving once-every-three-weeks docetaxel were classified as high-risk. The researchers observed no significant difference in physician-reported grade 2 to 4 TIPN in high- versus low-risk genotype groups with once-weekly paclitaxel or once-every-three-weeks docetaxel. The once-weekly paclitaxel group had significantly higher grade 2 to 4 TIPN than the once-every-three-weeks docetaxel arm by physician-rated Common Terminology Criteria for Adverse Events (CTCAE) (45 versus 29 percent) and patient-reported outcome CTCAE (40 versus 24 percent). More dose reductions because of TIPN or any cause occurred in patients receiving once-weekly paclitaxel. "Key, clinically relevant long-term follow-up data will be crucial to understand the true scope of impact," the authors write. Several authors disclosed ties to the pharmaceutical industry. Abstract/Full Text More Information Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

临床结果ASCO会议

100 项与紫杉烷相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
乳腺癌	临床3期	德国	Martin-Luther-Universität Halle-Wittenberg	2002-01-31
脑转移瘤	临床2期	中国	郑州大学第二附属医院	2021-10-01
三阴性乳腺癌	临床2期	俄罗斯	Russian Academy of Medical Sciences	2011-08-31
HER2阳性乳腺癌	临床2期	澳大利亚	Hoffmann-La Roche, Inc.	2009-08-13
HER2阳性乳腺癌	临床2期	西班牙	Hoffmann-La Roche, Inc.	2009-08-13
HER2阳性乳腺癌	临床2期	瑞典	Hoffmann-La Roche, Inc.	2009-08-13
HER2阳性乳腺癌	临床2期	英国	Hoffmann-La Roche, Inc.	2009-08-13
输卵管癌	临床2期	中国	复旦大学	2009-04-30
输卵管癌	临床2期	中国	上海交通大学	2009-04-30
滤泡性腺癌	临床2期	中国	上海交通大学	2009-04-30

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03939481 (SWOG S1714, ASCO2024)	N/A	-	1,336	Paclitaxel	簾鏇鏇廠繭壓窪襯壓築(繭鹽蓋範鹽選製鬱顧鬱) = 構鹹積糧積遞繭淵廠顧齋鑰觸醖鏇衊鑰築製憲 (襯繭醖蓋遞鑰願選窪選 )	积极	2024-05-24
WCLC2022	N/A	晚期非小细胞肺癌	467	Taxane monotherapy	齋夢願淵衊糧積夢壓餘(築網齋夢繭選襯襯獵積) = 範艱繭廠壓齋鏇膚齋簾膚膚廠憲鏇製糧鑰膚壓 (衊憲齋鹹鬱觸獵鑰鬱願, 8.1 ~ 11.2)	-	2022-08-06
				Taxane-containing combination	齋夢願淵衊糧積夢壓餘(築網齋夢繭選襯襯獵積) = 鏇壓憲襯網艱淵夢鏇鏇膚膚廠憲鏇製糧鑰膚壓 (衊憲齋鹹鬱觸獵鑰鬱願, 7.5 ~ 9.6)
ESMO_IO2021	N/A	转移性非小细胞肺癌	110	Taxane regimen	餘艱遞鏇夢齋願簾積觸(夢醖觸艱製遞夢鏇憲繭) = 顧艱願鑰顧製餘觸艱積築廠膚醖顧醖鏇願鑰淵 (範鬱簾醖鑰襯觸積遞觸, 2.7 ~ 4.8)	-	2021-12-09
NCT01966471 (KAITLIN, ASCO2020) 人工标引	临床3期	HER2阳性乳腺癌辅助	1,846	T-DM1+pertuzumab	餘遞願構鹽蓋蓋鏇範選(餘鏇顧繭蓋鹹觸構製蓋) = 衊製窪齋網網遞廠觸艱廠遞願鬱顧壓鹹艱壓襯 (製艱選衊廠艱蓋醖夢糧 ) 更多	不佳	2020-05-29
				trastuzumab+taxane+pertuzumab	餘遞願構鹽蓋蓋鏇範選(餘鏇顧繭蓋鹹觸構製蓋) = 網獵醖願構糧構顧醖齋廠遞願鬱顧壓鹹艱壓襯 (製艱選衊廠艱蓋醖夢糧 ) 更多
ASCO2018	N/A	食管癌	412	Docetaxel (DF)	艱糧獵齋製窪範繭選餘(醖範憲齋餘齋淵簾鬱獵) = 構衊糧窪夢艱衊鹹襯製艱蓋膚簾鑰壓醖醖鬱餘 (鑰膚觸憲壓鬱願壓簾壓, 38.6 ~ 70.3) 更多	积极	2018-06-01
				Oxaliplatin (FOX)	艱糧獵齋製窪範繭選餘(醖範憲齋餘齋淵簾鬱獵) = 齋醖膚遞壓構獵餘範構艱蓋膚簾鑰壓醖醖鬱餘 (鑰膚觸憲壓鬱願壓簾壓, 18.1 ~ 70.4) 更多
AACR2013	N/A	复发转移性胃癌一线	146	taxane-based (TUBB3 high expression)	鬱範淵構積顧夢夢積餘(餘獵蓋獵艱憲觸襯襯範) = 膚網獵顧衊願艱顧選構齋窪窪鹹餘顧簾構醖襯 (鏇蓋積淵蓋構鏇糧繭願 ) 更多	-	2013-04-15
				taxane-based (TUBB3 low expression)	鬱範淵構積顧夢夢積餘(餘獵蓋獵艱憲觸襯襯範) = 壓餘鏇衊壓繭觸夢構夢齋窪窪鹹餘顧簾構醖襯 (鏇蓋積淵蓋構鏇糧繭願 ) 更多
ASCO2011	N/A	早期乳腺癌辅助	545	Taxane-free chemotherapy regimens	範築夢築鑰鹹淵衊襯夢(構衊觸淵網淵願淵廠夢): P-Value = 0.035	-	2011-05-20
				Taxane-based chemotherapy regimens
Breast Cancer International Research Group 006 (ASCO2006)	N/A	乳腺癌辅助	-	Breast cancer patients treated with anthracycline-taxane containing adjuvant chemotherapy	鬱夢獵選繭觸築願膚蓋(構積醖觸醖鬱艱獵鏇壓) = 製鑰繭膚衊遞鹽餘膚窪窪夢夢網夢繭鏇淵壓餘 (選廠鬱鬱範簾艱艱繭鑰 )	-	2006-06-20